XETRA : 5CV.DE

CureVac N.V.

$3.906 EUR

$0.03 (0.72%)

Volume
125.27K
Average Volume
168.17K
Market Capitalization
$879.52M
P/E Ratio
5.43
Dividend Yield
0.00%
Price Target
Year High
$4.90
Year Low
$2.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.70
Company Overview

XETRA

Alexander Zehnder

Biotechnology

Healthcare

5CV.DE

825

DE

EUR

https://www.curevac.com

49 7071 9883 0

N/A

N/A

Liquidity Metrics

0.04

3.70

3.69

1.76

0.00

Sales & Valuation

$535.18M

15.63

1.01

-15.72

-0.25

Profitability

$0.72

$162.19M

287.15%

348.24%

23.04%

14.19%

P/E Metrics

5.43

0.39

0.39

Analyst Price Target & Rating

N/A

0/5

8 Analysts

%

Financial Health Scores

1.65

3/9

$636.94M

$1.14B

$267.39M

$163.58M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Malte Greune Chief Operating Officer, Member of Management Board & MD
Patrick Baumhof Senior Vice President of Technology
Sarah Fakih Vice President of Corporate Communications & Investor Relations
Axel-Sven Malkomes Chief Financial Officer & Member of Executive Board
Thaminda Ramanayake Chief Business Officer & Member of Executive Board
Slavica Stevanovic-Heck Head of Human Resources
Myriam Mendila Chief Scientific Officer, Head of R&D, MD & Member of the Management Board
Ulrike Gnad-Vogt Senior Vice President & Area Head of Oncology
Alexander Zehnder Chief Executive Officer, MD & Member of Management Board
Marco Rau General Counsel
Poll Results

No votes yet today — be the first to share your view!

About CureVac N.V. (XETRA:5CV.DE) Stock

CureVac N.V. is a biopharmaceutical entity operating in the clinical development phase, focused on pioneering revolutionary medicines utilizing messenger ribonucleic acid (mRNA) technology. Its portfolio includes prophylactic vaccines such as the mRNA-based candidate CV2CoV, currently in Phase 1 clinical trials for SARS-CoV-2. Another mRNA vaccine, CV7202, has successfully concluded Phase 1 trials for rabies, while CVSQIV is in Phase 1 development against influenza. The company is also advancing therapies for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Furthermore, CureVac is actively developing RNA-based immunotherapies for cancer, exemplified by CV8102, which is presently in Phase 1 clinical evaluation for cutaneous melanoma, adeno ... idcystic carcinoma, and squamous cell cancers affecting the skin, head, and neck. The company was established in 2000 and maintains its main office in Tübingen, Germany.

Frequently Asked Questions

What is the current CureVac N.V. (5CV.DE) stock price?

CureVac N.V.(XETRA:5CV.DE) stock price is $3.906 in the last trading session. During the trading session, 5CV.DE stock reached the peak price of $4.9 while $2 was the lowest point it dropped to. The percentage change in 5CV.DE stock occurred in the recent session was 0.72% while the dollar amount for the price change in 5CV.DE stock was $0.03.

5CV.DE's industry and sector of operation?

The XETRA listed 5CV.DE is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 5CV.DE?

Malte Greune | Chief Operating Officer, Member of Management Board & MD
Patrick Baumhof | Senior Vice President of Technology
Sarah Fakih | Vice President of Corporate Communications & Investor Relations
Axel-Sven Malkomes | Chief Financial Officer & Member of Executive Board
Thaminda Ramanayake | Chief Business Officer & Member of Executive Board

How many employees does 5CV.DE have?

Number of 5CV.DE employees currently stands at 825. 5CV.DE operates from Friedrich-Miescher-Strasse 15, Tübingen, None 72076, DE.

Link for 5CV.DE official website?

Official Website of 5CV.DE is: https://www.curevac.com

How do I contact 5CV.DE?

5CV.DE could be contacted at phone #49 7071 9883 0 and can also be accessed through its website. 5CV.DE operates from Friedrich-Miescher-Strasse 15, Tübingen, None 72076, DE.

How many shares of 5CV.DE are traded daily?

The average number of 5CV.DE shares traded daily for last 3 months was 168.17K.

What is the market cap of 5CV.DE currently?

The market value of 5CV.DE currently stands at $879.52M with its latest stock price at $3.906